ArticleJournal of clinical microbiology2017
A Modified Carbapenem Inactivation Method, CIMTris, for Carbapenemase Production in Acinetobacter and Pseudomonas Species.
Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Evaluation of carbapenem inactivation method-based phenotypic assays for the detection of GES-type carbapenemases in Enterobacterales,Journal of clinical microbiology · 2026Article
- The shift from "MIC-Only" back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance.Journal of clinical microbiology · 2026Review
- Performance evaluation of the NG-TEST CARBA 5 and Genobio K.N.I.V.O. detection K-Set lateral flow assays for the detection of carbapenemases.Microbiology spectrum · 2025Article
- Laboratory detection of carbapenemases among Gram-negative organisms.Clinical microbiology reviews · 2024Review
- Molecular genotyping reveals multiple carbapenemase genes and unique blaTropical medicine and health · 2024Article
- Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Complete sequence of carbapenem-resistantMicrobiology spectrum · 2024Article
- Evaluation of antimicrobial susceptibility tests for Acinetobacter and Pseudomonas species using disks containing a high dose of meropenem.Scientific reports · 2024Article
- False-positive imipenemase detected by NG-Test CARBA-5 in carbapenem-resistantMicrobiology spectrum · 2024Article
- Evaluation of NG-Test CARBA 5 version 2, Cepheid Xpert Carba-R, and carbapenem inactivation methods in comparison to whole-genome sequencing for the identification of carbapenemases in non-fermenting Gram-negative bacilli.Journal of clinical microbiology · 2023Article
- Diagnostic Performance of BD Phoenix CPO Detect Panels for Detection and Classification of Carbapenemase-Producing Gram-Negative Bacteria.Microbiology spectrum · 2023Article
- The optimized carbapenem inactivation method for objective and accurate detection of carbapenemase-producingFrontiers in microbiology · 2023Article
- Phenotypic and genotypic detection methods for antimicrobial resistance in ESKAPE pathogens (Review).Experimental and therapeutic medicine · 2022Review
- Evaluation of Three Carbapenemase-Phenotypic Detection Methods and Emergence of Diverse VIM and GES Variants amongAntibiotics (Basel, Switzerland) · 2022Article
- A Variant Carbapenem Inactivation Method (CIM) forPathogens (Basel, Switzerland) · 2022Article
- Genomic Investigation of TwoPathogens (Basel, Switzerland) · 2022Article
- Antimicrobial Resistance and Type III Secretion System Virulotypes of Pseudomonas aeruginosa Isolates from Dogs and Cats in Primary Veterinary Hospitals in Japan: Identification of the International High-Risk Clone Sequence Type 235.Microbiology spectrum · 2021Article
- Practical Agar-Based Disk Diffusion Tests Using Sulfamoyl Heteroarylcarboxylic Acids for Identification of Subclass B1 Metallo-β-Lactamase-ProducingJournal of clinical microbiology · 2021Article
- Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design.Chemical reviews · 2021Review
- Adjustment of Modified Carbapenem Inactivation Method Conditions for Rapid Detection of Carbapenemase-ProducingAnnals of laboratory medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The carbapenem inactivation method (CIM) and modified CIM (mCIM) are simple and economical phenotypic screening methods for detecting carbapenemase production in Gram-negative bacteria. Although the mCIM has been recommended by the Clinical and Laboratory Standards Institute, both the CIM and mCIM have limitations. This study describes another modified CIM, called CIMTris, in which carbapenemase was extracted from bacteria with 0.5 M Tris-HCl (pH 7.6) buffer. The ability of the CIMTris to detect carbapenemase production was examined in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.